A sec­ond wave of check­point in­hibitors is swelling fast, with speedy BeiGene leap­ing in­to a piv­otal tri­al

Every­body wants their own check­point in­hibitor, or so it may seem.

Now that the bi­ol­o­gy is thor­ough­ly un­der­stood, we’re see­ing a sec­ond wave of late-stage pro­grams tak­ing shape — each with their own niche mar­kets in mind for dis­rup­tion.

To­day, you can add Bei­jing-based Beigene $BGNE to that list.

The biotech dosed their first pa­tient with re­frac­to­ry clas­si­cal Hodgkin lym­phoma — or cHL — with their an­ti-PD-1 drug BGB-A317 in a piv­otal study.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER